학술논문
Hepatitis B seroprevalence among 5 to 6 years old children in the Philippines born prior to routine hepatitis B vaccination at birth.
Document Type
Academic Journal
Author
Lopez AL; a Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines Manila , Manila , Philippines.; Ylade M; a Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines Manila , Manila , Philippines.; Daag JV; a Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines Manila , Manila , Philippines.; Tandoc AO 3rd; b Department of Virology , Research Institute for Tropical Medicine , Muntinlupa , Philippines.; Bonifacio J; b Department of Virology , Research Institute for Tropical Medicine , Muntinlupa , Philippines.; Sylim PG; c National Telehealth Centre, National Institutes of Health, University of the Philippines Manila , Manila , Philippines.; Sy AK; b Department of Virology , Research Institute for Tropical Medicine , Muntinlupa , Philippines.; Centeno R; b Department of Virology , Research Institute for Tropical Medicine , Muntinlupa , Philippines.; Roque V Jr; d National Epidemiology Center, Department of Health , Manila , Philippines.; Ducusin MJ; e Family Health Office, Department of Health , Philippines.
Source
Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE
Subject
Language
English
Abstract
To assess the prevalence of hepatitis B in the Philippines, we conducted a cross-sectional study among 5 to 6 year old children born in 2007-2008, when the birth dose started to be implemented in the country. The study was conducted from 25 July to 22 October 2013 in 24 provinces and used a 3-stage cluster design and probability-proportional to size sampling. Blood was obtained and sera were tested for hepatitis B surface antigen (HBsAg). The survey included 2,769 children, of whom 26% received a timely birth dose (within 24 hours of birth) and 89% received 3 doses of the hepatitis B vaccine. Due to problems in the initial testing algorithm, only 2,407 sera were available for HBsAg testing, 20 (weighted%, 0.86%) were HBsAg positive. By immunization card and recall, among HBsAg positive children, 2 (weighted%, 20%) received a timely birth dose while 17 (weighted%, 85%) received 3 doses of the hepatitis B vaccine. The seroprevalence of HBsAg that we detected was lower than expected. However, there were several limitations in the field and in the laboratory that may have affected the representativeness of the results. Follow up studies need to be conducted to validate these results.